Methods to individualize combination therapy
    2.
    发明申请
    Methods to individualize combination therapy 审中-公开
    个性化联合治疗方法

    公开(公告)号:US20060228694A1

    公开(公告)日:2006-10-12

    申请号:US10551374

    申请日:2004-04-02

    IPC分类号: A61K38/17 C12Q1/00 C12Q1/68

    摘要: Compositions which comprise delivery vehicles having stably associated therewith predetermined, patient-specific combinations of two or more agents, such as antineoplastic agents, are useful in achieving optimal therapeutic effects on a patient-by-patient basis when combinations of drugs are administered.

    摘要翻译: 包含递送载体的组合物,当两种或更多种药物如抗肿瘤药物的预定的患者特异性组合具有稳定相关性时,可用于在施用药物组合时实现逐个患者的最佳治疗效果。

    Anhydrovinblastine for the treatment of cancer
    3.
    发明授权
    Anhydrovinblastine for the treatment of cancer 失效
    用于治疗癌症的脱氢长春花碱

    公开(公告)号:US06326376B1

    公开(公告)日:2001-12-04

    申请号:US09380540

    申请日:2000-01-21

    IPC分类号: A61K3144

    CPC分类号: A61K31/475

    摘要: The present invention is particularly directed to the use of a derivative of vinblastine, 3′,4′-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3′,4′ position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an anti-neoplastic agent in the therapeutic treatment of cancer.

    摘要翻译: 本发明特别涉及长春碱,3',4'-脱氢长春碱(AHVB)的衍生物,其与长春花碱不同,因为它在黄嘌呤核的3',4'位具有双键,而不是 比在母体结构中存在的羟基作为癌症治疗性治疗中的抗肿瘤剂。

    Liposomal formulations of anthracycline agents and cytidine analogs
    8.
    发明授权
    Liposomal formulations of anthracycline agents and cytidine analogs 有权
    蒽环类药物和胞苷类似物的脂质体制剂

    公开(公告)号:US08022279B2

    公开(公告)日:2011-09-20

    申请号:US11587112

    申请日:2005-04-22

    IPC分类号: A61K9/127

    摘要: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

    摘要翻译: 包含蒽环类药物和胞苷类似物的组合物被包封在脂质体载体中。 优选的蒽环类药物选自柔红霉素,多柔比星和伊达比星组,而优选的胞苷类似物选自阿糖胞苷,吉西他滨或5-氮杂胞苷组。 包封在所述脂质体载体中的蒽环类药物和胞苷类似物的组合可用于实现每种治疗剂的药物保留和持续的药物释放。

    LOCALIZED DELIVERY OF DRUG COMBINATIONS
    10.
    发明申请
    LOCALIZED DELIVERY OF DRUG COMBINATIONS 审中-公开
    药物组合的本地化交付

    公开(公告)号:US20090304766A1

    公开(公告)日:2009-12-10

    申请号:US12095494

    申请日:2006-11-30

    申请人: Lawrence Mayer

    发明人: Lawrence Mayer

    IPC分类号: A61F2/04

    摘要: Implants comprising controlled delivery matrices, associated with, or including medical devices, having stably and releasably associated therewith predetermined non-antagonistic combinations of two or more therapeutic agents provide control of the ratio of these agents at a localized site. Methods of identifying such combinations are also disclosed.

    摘要翻译: 包含受控递送基质的植入物,与具有稳定和可释放地相关联的两种或更多种治疗剂的预定非拮抗性组合的与医疗装置相关联或包括医疗装置的控制递送基质提供了这些药剂在局部位点处的比率的控制。 还公开了识别这种组合的方法。